Retatrutide vs Tirzepatide: What the Hype Is Actually About
Every few months the internet picks a new favorite molecule. Right now the retatrutide vs tirzepatide debate is the main event, and most of the takes I see are based on one number someone saw in a screenshot.

I read the papers so you don't have to. Let's compare these two properly, with the caveats attached.
The receptor math
Tirzepatide is a dual agonist. It activates the GLP-1 receptor and the GIP receptor. It's made by Eli Lilly and sold as Mounjaro (for type 2 diabetes) and Zepbound (for weight management). Both are FDA-approved. This is a real, prescribable drug.
Retatrutide adds a third target: the glucagon receptor. So it's GLP-1 plus GIP plus glucagon, which is why people call it "triple G." Also Lilly. Not approved. It's in phase 3 trials, meaning it's still a research compound.
The pitch for the third receptor is that glucagon signaling may increase energy expenditure. GLP-1 and GIP mostly work on appetite and blood sugar. Add glucagon and, in theory, you're pushing on both sides of the energy balance equation.
"In theory" is doing a lot of work in that sentence. Keep that in mind.
Retatrutide vs tirzepatide on the numbers
Here's what the trials actually reported.
Tirzepatide's SURMOUNT-1 trial ran 72 weeks. The top group lost about 20.9% of body weight on average. That's a phase 3 trial with over 2,500 participants, which is why the FDA approved it.
Retatrutide's phase 2 trial ran 48 weeks. The top group lost about 24.2% on average. That's a smaller study, around 340 people, and it's phase 2. The weight loss curve also hadn't flattened out when the trial ended, which is what everyone finds so exciting.
So yes, 24 beats 21. But you're comparing a phase 2 study to a phase 3 study, with different lengths, different populations, and different levels of scrutiny. A good scientist would say "promising, let's see phase 3." Reddit says "tirz is obsolete."
Reddit is wrong about that, for the record. A number from a smaller trial doesn't retire an approved medication.
Side effects: same family, same complaints
Both compounds produce the classic GLP-1 gut effects: nausea, vomiting, constipation, diarrhea. These were the most common adverse events in both trials.
Retatrutide's trial also reported small increases in heart rate, and some skin sensation effects that showed up in a subset of participants. Whether those matter long-term is exactly the kind of thing phase 3 is designed to answer.
If anyone tells you one of these has "no side effects," they haven't read a single table in either paper.
Availability is the real difference
This is the part that actually shapes the debate.
Tirzepatide is a prescription drug. Compounded versions had a window while it was on the FDA shortage list, but the FDA removed it from that list, and Lilly has been suing compounders, telehealth outfits, and sellers ever since. That route has gotten narrow.
Retatrutide has no prescription route at all. It only exists as a research compound. Nothing sold online is approved by the FDA for any use, and that's not a technicality. It's the whole situation.
That means retatrutide lives entirely in the research-vendor world, which is a world with real quality problems. Fake COAs, crypto-only checkout, warm shipping, vendors that disappear. Anyone comparing these two compounds without mentioning that isn't giving you the full picture.
Where the hype is fair and where it isn't
Fair: retatrutide has the most impressive early weight-loss data of any single molecule so far. The three-receptor idea is scientifically interesting. Lilly is investing heavily in it.
Not fair: treating phase 2 results as settled, ignoring the safety questions phase 3 exists to answer, and pretending the sourcing situation is the same for both.
My honest position is that both are worth studying and neither is magic.
If you're sourcing for research
Pick a vendor that publishes lab work instead of vibes. Exactide sells research-grade retatrutide and tirzepatide with batch-specific COAs, third-party tested to 99% purity or higher. They ship cold, domestically, in 2 to 4 business days, with free shipping over $150 and normal payment methods.
Read the studies, ignore the screenshots, and if you need research-grade material, Exactide is the sensible place to get it.
Get a new guide every week.
Subscribe free and the Beginner's Guide to Peptide Research is yours instantly.
